These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 19817806)

  • 1. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
    Wong M
    Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway.
    Zeng LH; Rensing NR; Wong M
    Mol Cell Pharmacol; 2009 Jan; 1(3):124-129. PubMed ID: 20419051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
    Rensing N; Han L; Wong M
    Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.
    McDaniel SS; Wong M
    Neurosci Lett; 2011 Jun; 497(3):231-9. PubMed ID: 21354266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian target of rapamycin (mTOR) pathways in neurological diseases.
    Wong M
    Biomed J; 2013; 36(2):40-50. PubMed ID: 23644232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy.
    Ryther RC; Wong M
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):410-8. PubMed ID: 22544534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy.
    Jeong A; Wong M
    Expert Rev Neurother; 2016; 16(4):437-47. PubMed ID: 26854692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
    Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
    Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of mTOR inhibitors in epilepsy treatment.
    Sadowski K; Kotulska-Jóźwiak K; Jóźwiak S
    Pharmacol Rep; 2015 Jun; 67(3):636-46. PubMed ID: 25933981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models of focal cortical dysplasia and tuberous sclerosis complex: recent progress toward clinical applications.
    Wong M
    Epilepsia; 2009 Oct; 50 Suppl 9(0 9):34-44. PubMed ID: 19761452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target.
    Galanopoulou AS; Gorter JA; Cepeda C
    Epilepsia; 2012 Jul; 53(7):1119-30. PubMed ID: 22578218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy.
    Zeng LH; Rensing NR; Wong M
    J Neurosci; 2009 May; 29(21):6964-72. PubMed ID: 19474323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.
    Wong M
    Exp Neurol; 2013 Jun; 244():22-6. PubMed ID: 22015915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR dysregulation and tuberous sclerosis-related epilepsy.
    Curatolo P; Moavero R; van Scheppingen J; Aronica E
    Expert Rev Neurother; 2018 Mar; 18(3):185-201. PubMed ID: 29338461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
    Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
    Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
    Zhang B; McDaniel SS; Rensing NR; Wong M
    PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the mTOR signaling pathway in epilepsy.
    Meng XF; Yu JT; Song JH; Chi S; Tan L
    J Neurol Sci; 2013 Sep; 332(1-2):4-15. PubMed ID: 23773767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
    Nguyen LH; Mahadeo T; Bordey A
    J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.
    Jeong A; Wong M
    J Child Neurol; 2018 Jan; 33(1):55-63. PubMed ID: 29246093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.